Population Pharmacokinetics of Cefazolin in Serum and Adipose Tissue From Overweight and Obese Women Undergoing Cesarean Delivery

Journal of Clinical Pharmacology

Volumn 57, Issue 6, 2017, Pages 712-719

  Grupper, Mordechai ^a   Kuti, Joseph L ^a   Swank, Morgan L ^b   Maggio, Lindsay ^c   Hughes, Brenna L ^d   Nicolau, David P ^a  

^a HARTFORD HOSPITAL   (United States)

^b Millers Children's Hospital   (United States)

^c UNIVERSITY OF SOUTH FLORIDA   (United States)

^d BROWN UNIVERSITY   (United States)

Author keywords

Monte Carlo simulation; obesity; pharmacokinetics; prophylaxis; surgery

Indexed keywords

CEFAZOLIN; ANTIINFECTIVE AGENT;

ADIPOSE TISSUE; ADULT; ARTICLE; BODY MASS; CESAREAN SECTION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG PENETRATION; DRUG TISSUE LEVEL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MINIMUM INHIBITORY CONCENTRATION; MONTE CARLO METHOD; OBESITY; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; VOLUME OF DISTRIBUTION; ANTIBIOTIC PROPHYLAXIS; BIOLOGICAL MODEL; BLOOD; METABOLISM; MICROBIAL SENSITIVITY TEST; PREGNANCY; YOUNG ADULT;

ADIPOSE TISSUE; ADULT; ANTI-BACTERIAL AGENTS; ANTIBIOTIC PROPHYLAXIS; CEFAZOLIN; CESAREAN SECTION; FEMALE; HUMANS; MICROBIAL SENSITIVITY TESTS; MODELS, BIOLOGICAL; MONTE CARLO METHOD; OVERWEIGHT; PREGNANCY; YOUNG ADULT;

EID: 85008258241     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.851     Document Type: Article

References (31)

1. Imes CC, Burke LE. The obesity epidemic: the United States as a cautionary tale for the rest of the world. Curr Epidemiol Rep. 2014;1:82–88.
2. Ogden CL, Carroll MD, Kit BK, Flegal KM. Prevalence of childhood and adult obesity in the United States, 2011-2012. JAMA. 2014;26:806–814.
3. American College of Obstetricians and Gynecologists. ACOG Committee opinion no. 549: obesity in pregnancy. Obstet Gynecol. 2013;121:213–217.
4. Martin JA, Hamilton BE, Osterman MJK. Births in the United States, 2014. NCHS Data Brief. 2015;216:1–8.
5. Tita AT, Rouse DJ, Blackwell S, Saade GR, Spong CY, Andrews WW. Emerging concepts in antibiotic prophylaxis for cesarean delivery: a systematic review. Obstet Gynecol. 2009;113:675–682.
6. Dhar H, Al-Busaidi I, Rathi B, Nimre EA, Sachdeva V, Hamdi I. A study of post-caesarean section wound infections in a regional referral hospital, oman. Sultan Qaboos Univ Med J. 2014;14:e211–e217. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3997538/.
7. Robinson HE, O'Connell CM, Joseph KS, McLeod NL. Maternal outcomes in pregnancies complicated by obesity. Obstet Gynecol. 2005;106:1357–1364.
8. American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 120: Use of prophylactic antibiotics in labor and delivery. Obstet Gynecol. 2011;117:1472–1483.
9. Alanis MC, Villers MS, Law TL, Steadman EM, Robinson CJ. Complications of cesarean delivery in the massively obese parturient. Am J Obstet Gynecol. 2010;203:e1–e7. doi: 10.1016/j.ajog.2010.06.049.
10. Falagas ME, Karageorgopoulos DE. Adjustment of dosing of antimicrobial agents for bodyweight in adult. Lancet. 2010;16:248–251.
11. Tucker CE, Lockwood AM, Nguyen NH. Antibiotic dosing in obesity: the search for optimum dosing strategies. Clin Obes. 2014;4:287–295.
12. Unger NR, Stein BJ. Effectiveness of pre-operative cefazolin in obese patients. Surg Infect (Larchmont). 2014;15:412–416.
13. Swank ML, Wing DA, Nicolau DP, McNulty JA. Increased 3-gram cefazolin dosing for cesarean delivery prophylaxis in obese women. Am J Obstet Gynecol. 2015;213:e1–e8. doi: 10.1016/j.ajog.2015.05.030.
14. Maggio L, Nicolau DP, DaCosta M, Rouse DJ, Hughes BL. Cefazolin prophylaxis in obese women undergoing cesarean delivery: a randomized controlled trial. Obstet Gynecol. 2015;125:1205–1210.
15. Young OM, Shaik IH, Twedt R, et al. Pharmacokinetics of cefazolin prophylaxis in obese gravidae at time of cesarean delivery. Am J Obstet Gynecol. 2015;213:e1–e7. doi: 10.1016/j.ajog.2015.06.034.
16. Pevzner L, Swank M, Krepel C, Wing DA, Chan K, Edmiston CE Jr. Effects of maternal obesity on tissue concentrations of prophylactic cefazolin during cesarean delivery. Obstet Gynecol. 2011;117:877–882.
17. Ho VP, Nicolau DP, Dakin GF, et al. Cefazolin dosing for surgical prophylaxis in morbidly obese patients. Surg Infect (Larchmont). 2012;13:33–37.
18. Neely MN, van Guilder MG, Yamada WM, Schumitzky A, Jelliffe RW. Accurate detection of outliers and subpopulations with Pmetrics, a nonparametric and parametric pharmacometric modeling and simulation package for R. Ther Drug Monit. 2012;34:467–476.
19. Yamaoka K, Nakagawa T, Uno T. Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations. J Pharmacokinet Biopharm. 1978;6:165–175.
20. Bhalodi AA, Housman ST, Shepard A, Nugent J, Nicolau DP. Tissue pharmacokinetics of cefazolin in patients with lower limb infections. Antimicrob Agents Chemother. 2013;57:5679–5683.
21. Housman ST, Sutherland CA, Nicolau DP. Pharmacodynamic profile of commonly utilised parenteral therapies against methicillin-susceptible and methicillin-resistant Staphylococcus aureus collected from US hospitals. Int J Antimicrob Agents. 2014;44:235–241.
22. CLSI. CLSI Supplement M100S. Performance Standards for Antimicrobial Susceptibility Testing, 26th ed. Wayne, PA: Clinical and Laboratory Standards Institute; 2016.
23. Allegaert K, van Mieghem T, Verbesselt R, et al. Cefazolin pharmacokinetics in maternal plasma and amniotic fluid during pregnancy. Am J Obstet Gynecol. 2009;200:e1–e7. doi: 10.1016/j.ajog.2008.08.067.
24. Elkomy MH, Sultan P, Drover DR, Epshtein E, Galinkin JL, Carvalho B. Pharmacokinetics of prophylactic cefazolin in parturients undergoing cesarean delivery. Antimicrob Agents Chemother. 2014;58:3504–3513.
25. Philipson A, Stiernstedt G, Ehrnebo M. Comparison of the pharmacokinetics of cephradine and cefazolin in pregnant and non-pregnant women. Clin Pharmacokinet. 1987;12:136–144.
26. Rattie ES, Ravin LJ. Pharmacokinetic interpretation of blood levels and urinary excretion data for cefazolin and cephalothin after intravenous and intramuscular administration in humans. Antimicrob Agents Chemother. 1975;7:606–613.
27. Brill MJ, Houwink AP, Schmidt S, et al. Reduced subcutaneous tissue distribution of cefazolin in morbidly obese versus non-obese patients determined using clinical microdialysis. J Antimicrob Chemother. 2014;69:715–723.
28. Kiang TK, Häfeli UO, Ensom MH. A comprehensive review on the pharmacokinetics of antibiotics in interstitial fluid spaces in humans: implications on dosing and clinical pharmacokinetic monitoring. Clin Pharmacokinet. 2014;53:695–730.
29. Faro S, Phillips LE, Martens MG. Perspectives on the bacteriology of postoperative obstetric-gynecologic infections. Am J Obstet Gynecol. 1988;158:694–700.
30. Cefazolin package insert. http://www.sagentpharma.com/wp-content/uploads/2014/11/Cefazolin_PI1.pdf. Accessed February 15, 2016.
31. Van Hasselt JGC, Allegaert K, van Calsteren K, Beijnen JH, Schellens JHM, Huitema ADR. Semiphysiological versus empirical modelling of the population pharmacokinetics of free and total cefazolin during pregnancy. Bio Med Res Int. 2014;2014:897216. doi:10.1155/2014/897216.